|
gptkbp:instance_of
|
gptkb:legal_case
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Repatha
|
|
gptkbp:analysis
|
statistical analysis
|
|
gptkbp:analyzes
|
gptkb:Dr._John_Doe
|
|
gptkbp:business_model
|
obtained
|
|
gptkbp:clinical_trial
|
Phase III
clinicaltrials.gov
NC T03425044
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:collection
|
patient-reported outcomes
|
|
gptkbp:committee
|
gptkb:battle
|
|
gptkbp:criteria
|
pregnant or breastfeeding women
diagnosed with relapsing MS
|
|
gptkbp:duration
|
24 months
|
|
gptkbp:events
|
2 years
|
|
gptkbp:finale_date
|
reduction in relapse rate
|
|
gptkbp:focuses_on
|
gptkb:psychologist
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DESCARTES trial
|
|
gptkbp:is_protected_by
|
parallel assignment
treatment with ofatumumab
|
|
gptkbp:is_studied_in
|
completed
randomized controlled trial
|
|
gptkbp:is_tested_for
|
Phase III
|
|
gptkbp:launch_date
|
2018-01-01
|
|
gptkbp:location
|
multiple countries
|
|
gptkbp:outcome
|
MRI scans
|
|
gptkbp:participants
|
efficacy of treatment
adults with relapsing forms of multiple sclerosis
safety of treatment
|
|
gptkbp:population
|
diverse population
|
|
gptkbp:primary_source
|
treatment
|
|
gptkbp:products
|
gptkb:ofatumumab
|
|
gptkbp:provides_information_on
|
available upon request
|
|
gptkbp:publishes
|
gptkb:battle
peer-reviewed article
|
|
gptkbp:receives_funding_from
|
gptkb:Company
grants and sponsorships
|
|
gptkbp:recorded_by
|
randomized
800 participants
|
|
gptkbp:recruitment
|
ongoing
|
|
gptkbp:regulatory_compliance
|
pending
|
|
gptkbp:research
|
positive efficacy
Is ofatumumab effective?
|
|
gptkbp:result
|
2022-05-01
|
|
gptkbp:side_effect
|
gptkb:battle
|
|
gptkbp:sponsor
|
gptkb:Novartis
|
|
gptkbp:treatment
|
gptkb:battle
|
|
gptkbp:vision
|
double-blind
|
|
gptkbp:year
|
2021-12-31
2020-12-31
|